Skip to main content

Table 3 Summary of reports of SGLT2 inhibitor use in diabetic renal transplant patients

From: Two Japanese patients with stage G3b chronic kidney disease and impaired glucose metabolism after renal transplantation successfully treated with empagliflozin

Number of cases Age (years), mean ± SD or (range) Sex, male/female eGFR (mL/min/1.73 m2); baseline changes after SGLT2 inhibitor HbA1c (%); baseline changes after SGLT2 inhibitor Systolic blood pressure (mmHg); baseline changes after SGLT2 inhibitor Diastolic blood pressure (mmHg); baseline changes after SGLT2 inhibitor Body weight (kg); baseline changes after SGLT2 inhibitor References
14 56.5 ± 7.9 7/7 54.0 ± 23.8; 53.5 ± 13.3 6.7 ± 0.7; 7.1 ± 0.8 150 ± 26; 145 ± 20 86 ± 14; 76 ± 11 83.7 ± 7.6; 78.7 ± 7.7 [15]
22 63 (31–72) 17/5 66 (57–68); 59 (52–67) 6.9 (6.5–8.2); 6.9 (6.4–7.4) 143 (111–176); 140 (100–163) 76 (71–82); 80 (74–86) 92.0 (81.8–104.5); 85.0 (79.5–97.5) [16]
4 (SPKTR) 49.4 ± 8.9 2/2 60 ± 14; a− 4.3 ± 12.2 7.4 ± 1.1; a− 0.84 ± 1.2 Not provided; a− 6.5 ± 10.8 Not provided; a− 4.8 ± 12 Not provided; a− 2.14 ± 2.8 [17]
6 (KTR) 61. ± 12.6 5/1 78 ± 18.2; a− 4.3 ± 12.2 8.6 ± 1.4; a− 0.84 Not provided; a− 6.5 ± 10.8 Not provided; a− 4.8 ± 12 Not provided; a− 2.14 ± 2.8
24 53.8 ± 7.1 23/1 Ccr 86 ± 20; 83 ± 18 8.5 ± 1.5; 7.6 ± 1.0 142 ± 21; 134 ± 17 81 ± 9; 79 ± 8 78.6 ± 12.1; 76.2 ± 10.9 [18]
8 56.8 ± 13.7 6/2 75.75 ± 13.38; 69.88 ± 14.70 9.34 ± 1.36; 7.41 ± 1.44 135 ± 9.59; 126.43 ± 11.46 80.63 ± 10.13; 74.75 ± 7.25 BMI 32.74 ± 7.2; 27.4 ± 4.2 [19]
  1. SPKTR simultaneous pancreas-kidney transplant recipients, KTR kidney transplant recipients
  2. aAmount of change in both the SPKTR and KTR groups; mean ± SD